“…A major challenge in the treatment of glioblastoma is the insufficiency of the standard radiation dose to effectively control the tumor. Supporting this notion is the observation of many publications that 75–93 % of recurrences/progressions manifest within the primary tumor area [6] , [7] , [8] , [9] , [10] . To address this concern, several trials have explored dose escalation concepts, with some studies reporting favorable outcomes in terms of OS and progression-free survival (PFS) [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] .…”